InvestorsObserver
×
News Home

Where Does Foghorn Therapeutics Inc. (FHTX) Stock Fall in the Biotechnology Field After It Is Higher By 106.27% This Week?

Tuesday, February 13, 2024 01:15 PM | InvestorsObserver Analysts

Mentioned in this article

Where Does Foghorn Therapeutics Inc. (FHTX) Stock Fall in the Biotechnology Field After It Is Higher By 106.27% This Week?

Foghorn Therapeutics Inc. (FHTX) is near the top in its industry group according to InvestorsObserver. FHTX gets an overall rating of 77. That means it scores higher than 77 percent of stocks. Foghorn Therapeutics Inc. gets a 92 rank in the Biotechnology industry. Biotechnology is number 20 out of 148 industries.

Overall Score - 77
FHTX has an Overall Score of 77. Find out what this means to you and get the rest of the rankings on FHTX!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Foghorn Therapeutics Inc. Stock Today?

Foghorn Therapeutics Inc. (FHTX) stock has risen 5.54% while the S&P 500 has fallen -1.34% as of 1:13 PM on Tuesday, Feb 13. FHTX is up $0.34 from the previous closing price of $6.23 on volume of 138,406 shares. Over the past year the S&P 500 is higher by 19.76% while FHTX has fallen -3.66%. FHTX lost -$2.47 per share the over the last 12 months. Click Here to get the full Stock Report for Foghorn Therapeutics Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App